Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LICoRN-01: Immunogel + RFA for Colorectal Liver Metastases
NCT04062721Phase 1Not yet recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Aug 2025
- Primary completion
- Nov 2028
- Modality
- Recombinant Proteins and Enzymes, Targeted Liposomes, Stealth (PEGylated) Liposomes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of mifamurtide and sargramostim in colorectal cancer (CRC), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Incidence of treatment-emergent adverse events at 3 months. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
mifamurtidesargramostim
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04062721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04062721.